Pfizer announced Tuesday that its experimental COVID-19 pill appears effective against the omicron variant.

In an analysis of 2,246 adult participants, the vaccine-maker said results had been consistent with interim analysis announced in November that showed COVID-19 oral antiviral candidate Paxlovid had “significantly reduced the risk of hospitalization or death for any cause by 89% compared to placebo in non-hospitalized, high-risk adult patients with COVID-19 treated within three days of symptom onset.”

“In a secondary endpoint, PAXLOVID reduced the risk of hospitalization or death for any cause by 88% compared to placebo in patients treated within five days of symptom onset, an increase from the 85% observed in the interim analysis,” Pfizer said in a press release.

The data has been shared with the Food and Drug Administration (FDA) as part of an ongoing rolling submission for emergency use authorization (EUA).